FORMULATION AND METHOD FOR ERADICATING VIRUSES AND SPIKE PROTEINS

Abstract

Disclosed is a formulation to eradicate viruses and spike proteins or related proteins. The formulation includes one or more phyto support complexes, one or more supplements and one or more excipients. Further a method of action of formulation for targeting spike protein is disclosed. The method includes disrupting cell membranes of virus-producing cells to release viral components into the extracellular environment; and preventing viral attachment to target cells by employing agents that inhibit receptor-binding domains.

Description

1 TARIFF FOR DESTROYING VIRUSES AND SPIKE PROTEINS. FORMULATION AND METHOD TECHNICAL FIELD The currently described invention relates to the destruction of viruses and their associated proteins. Furthermore... In detail, the invention described herein is designed to destroy viruses and spike proteins. It is related to a formulation and method for that purpose. BACKGROUND A virus is surrounded by a protective protein shell called a capsid, which contains a molecule made of DNA or RNA, such as RNA. It is a microorganism consisting of a nucleic acid core. Like coronaviruses, it has a membrane-bound membrane. In viruses, these proteins are derived from host cell membranes and typically contain spike glycoproteins. An additional lipid membrane is present. The spike protein is similar to angiotensin in the case of SARS-CoV-2. through specific interactions with cellular receptors such as transforming enzyme 2 (ACE2) By binding to and entering host cells, it mediates viral transmission. It plays a critical role. This interaction triggers a series of cellular events that facilitate viral replication. It initiates. Beyond their role in the entry of the virus into the cell, spike proteins also play a role in vascular processes. including endothelial damage, immune dysregulation, and inflammatory responses It also plays a role in pathogenic mechanisms. These processes are associated with viral infections. It contributes significantly to the pathology and the spike protein is suitable for therapeutic interventions. He emphasizes that it is a key objective. Current strategies to mitigate viral infections include vaccination and hygiene. Vector control and antiviral chemotherapeutics are included. However, current strategies... Significant limitations still exist. It generally targets the viral spike protein. Vaccines can cause pathogenic effects such as inflammation, endothelial tissue damage, and potential neurological effects. It has shown side effects. Spikes, as observed in post-acute sequelae (PASC). The persistent presence of this protein is associated with prolonged inflammatory responses and tissue damage. The data revealed the persistence of the spike protein in critical areas such as bone marrow. This demonstrates its potential as a primary contributing factor to viral toxicity. It emphasizes addressing viral spike protein pathologies such as TNF-α-dependent pathways. Current methods for this focus mainly on post-acute sequelae, and 2 It is insufficient to comprehensively address the broader spectrum of associated toxic effects. It remains. Therefore, to overcome the problems mentioned above, we need to eliminate viruses and spikes. An effective formulation and method to destroy their proteins is needed. BRIEF DESCRIPTION One aspect of the currently described invention is to target the spike protein or related protein. A formulation is presented. The formulation has a range of 15% w / v to 25% w / v. or more phytonutrient complexes, one or more in the range of 5% w / v to 10% w / v. more supplements and one or more adjuvants in the range of 50% w / v to 60% w / v It contains an excipient. In some aspects of the currently described invention, the phyto-support complex may also include one or more It contains multiple chelating agents and one or more senolytic compounds. In some respects, one or more phyto-support complexes also contribute to the entire chelation process. It includes agents and all senolytic compounds. In some aspects of the currently described invention, one or more chelating agents, 5% w / v Fucoidan brown algae in the range of 15% w / v to 3% w / v to 7% w / v; humic acid acid; clinoptilolite tuff in the range of 2% w / v to 5% w / v; 1% w / v to 4% w / v Citrus pectin; in the range of 1% w / v to 3% w / v. Spirulina maxima; in the range of 0.5% w / v to 3% w / v. silicon dioxide in the range of 0.5% w / v to 3% w / v; ethylenediaminetetraacetic acid in the range of 0.5% w / v to 3% w / v (EDTA); and diethylenetriaminepentaacetic acid (DTPA) from 0.5% w / v to 2% w / v. They are selected from a group that includes all of these. All of them are sourced from India. In some aspects of the currently described invention, one or more senolitic compounds are used, 1% w / v Quercetin to 5% w / v; routine from 1% w / v to 4% w / v; 0.5% w / v to 3% EGCG in the w / v range; curcumin in the range of 0.5% w / v to 2% w / v; 0.5% w / v to 2% w / v resveratrol in the range; fisetin from 0.5% w / v to 2% w / v; 1% w / v to 4% w / v glycyrrhizic acid in the range of 0.5% w / v to 2% w / v; ginkgolide / bilobalid in the range of 5% w / v to 15% w / v of fucoidan brown algae; 3% w / v to 7% w / v of humic acid. acid; clinoptilolite tuff in the range of 2% w / v to 5% w / v; 1% w / v to 4% w / v modified citrus pectin; Spirulina maxima in the range of 1% w / v to 3% w / v; and 0.5% 3 They are selected from a group containing silicon dioxide in the range of w / v to 3% w / v. All of these It is sourced from India. In some aspects of the currently described invention, one or more additives, minerals, containing vitamins, antioxidants, enzymes, amino acids, probiotics and prebiotics They are selected from a group. All of them are sourced from India. In some aspects of the currently described invention, one or more auxiliary substances, solvent, water, oil, drying agent, anti-caking agent, binders, from a group that includes stabilizers, preservatives, emulsifiers and pH adjusters. They are selected. All of these are sourced from India. One aspect of the currently described invention is the ability to target viruses and their spike proteins or related proteins. a formulation for preparing a solution to eliminate proteins The method is explained. The method includes the following steps: obtaining a homogeneous mixture. Accordingly, phytosupport complex components in the range of 15% w / v to 25% w / v are added to a medium. addition of one or more chelating agents in the range of 0.1% w / v to 10% w / v and homogeneous one or more senolitic compounds in the range of 0.05% w / v to 5% w / v to be added to the mixture and then one or more in the range of 5% w / v to 10% w / v supplement and one or more excipients in the range of 50% w / v to 60% w / v (Water) is added to the homogeneous mixture. This step also involves raising the pH of the homogeneous mixture to 3. the temperature should be set to between 5 and 5, and the homogeneous mixture should be at a temperature of 50 to 60 degrees Celsius. It involves heating. In some aspects of the currently described invention, the method also involves homogeneous mixing. It involves mixing and grinding the mixture to create a homogeneous mixture; thus, a uniform particle. The size is obtained. One aspect of the currently described invention is to target the spike protein or related protein. The method of action of the formulation is explained. The method involves targeting viral components in cells. The breakdown of the cell membranes of virus-producing cells to release them into the external environment; and Targeting viral attachment using agents that inhibit receptor binding sites This involves preventing it from happening to the cells. In some respects, a treatment method is being described. The method involves a. viral components in the cells. a. the breakdown of the cell membranes of virus-producing cells to release them into the external environment; and b. 4 To inhibit the receptor binding sites of the spike protein, 15% w / v to 25% w / v one or more phytonutrient complexes within the range of 5% w / v to 10% w / v one or more supplements within the range of; and one in the range of 55% w / v to 65% w / v or by applying a formulation containing more or less excipients to the target This involves preventing viral attachment to cells. In some respects, for the destruction of viruses, spike proteins and related proteins, One or more phytonutrient complexes in the range of 15% w / v to 25% w / v; 5% One or more supplements ranging from w / v to 10% w / v; and 55% w / v to 65% The use of a formulation containing one or more excipients in the w / v range An explanation is provided. In some ways, the detoxification protocol targets freely floating substances in the bloodstream. regarding the enzymatic breakdown of viral particles and / or spike proteins It includes an additional step. This step involves the senolytic-mediated clearance of infected cells. and in parallel with the application of spike-binding agents to prevent viral re-entry. This is carried out using appropriate enzymes such as nattokinase, serrapeptase, bromelain, or Proteolytic agents such as other proteases that can break down viral proteins or spike structures. It includes, but is not limited to, enzymes. These enzymes are involved in general detoxification. To increase its effectiveness and safety, it can be administered orally, intravenously, or as a senolytic agent. It can be administered in combination with binding agents. In some respects, the provocation protocol is a formulation called "Revive". application of the capsules followed by simultaneous or sequential administration of the enzymatic component It may include being given as. In some respects, the detoxification protocol takes approximately 1.5–1 hours after the administration of senolytic compounds. After 2 hours, it causes a temporary increase in circulating spike protein levels. This The phenomenon involves the selective destruction of aged or virus-containing cells. This results in the release of intracellular spike proteins into the bloodstream. A temporary spike increase, a persistent spike, or viral presence otherwise under basal conditions. In cases where it cannot be detected, it is possible to perform a highly sensitive diagnostic test. This approach, referred to as the "provocation protocol," is implemented after the event. Measurement of spike protein levels within 1–4 hours using a spike-specific test. It resulted in... In some respects, the detoxification protocol also follows senolytic-mediated cell cleansing. free-floating spike proteins and / or viral particles released into the bloodstream It also involves enzymatic breakdown. Suitable enzymes include nattokinase, serrapeptase, bromelain, or other proteases capable of degrading spike protein structures It is found. Enzymatic breakdown increases the efficiency and safety of detoxification. for this purpose, simultaneously with or from the senolytic and spike binding steps. This can happen later. Since nattokinase acts extracellularly, it requires enzymatic activity. Cell lysis by senolytic agents is a prerequisite. In some respects, it involves the detoxification of viruses or spike proteins in a subject. A method is described that includes the following: (a) selective use of virus-containing cells by one or more senolytic agents its disintegration as; (b) application of one or more spike-binding agents to the host cell by blocking their receptors and inhibiting fusion enzymes Preventing the re-entry of viral or spike proteins into host cells; and (c) one or more of the following capable of performing proteolytic degradation of viral proteins by applying more enzymes, freely floating in the bloodstream Breakdown of virus and / or spike proteins. In some respects, this method involves the enzyme nattokinase. In some respects, the enzymes nattokinase, serrapeptase, bromelain, or some of these... It is selected from combinations. In some respects, the detection of persistent intracellular spike proteins for diagnostic purposes to increase the dose, approximately 1.5–2 hours after application of the senolytic agent. It is a method aimed at temporarily increasing circulating spike protein levels. BRIEF DESCRIPTION OF THE DRAWINGS The above-mentioned and other features and advantages of the currently described invention, Especially when considered together with the attached drawings, the following detailed explanation is provided. This becomes clearly evident upon examination; here: 6 Figure 1 shows the formulation in accordance with one aspect of the currently described invention. It shows a flowchart illustrating a method for its preparation. Figure 2 illustrates an aspect of the currently described invention, namely the spike proteins or a flowchart showing the mechanism of action of the formulation to target the relevant proteins It shows the diagram; Figure 3 shows how to eliminate viruses and spike proteins or related proteins through formulation. It shows a schematic representation of a method for doing something. Figure 4 shows a graphical representation of spike proteins circulating in the blood. To make it easier to understand, they share common shapes where possible. Reference numbers were used to identify similar elements. DETAILED EXPLANATION Various aspects of the currently described invention are designed to destroy viruses and spike proteins. It presents a formulation and a method for this purpose. The following explanation outlines these aspects. In order to ensure a comprehensive understanding, shown in the drawings It provides specific details regarding particular aspects of the statement. However, The currently disclosed invention may also be reflected in additional directions and the disclosure is as follows: It should be acknowledged that it can be implemented even without some of the details mentioned in the explanation. Various aspects, including exemplary aspects, illustrate the various aspects of the described invention. This is now explained more fully, with reference to the attached illustrations. However, the invention declaration can be made in different forms, and here This should not be interpreted as being limited to the aspects mentioned. Rather, these aspects should be interpreted as encompassing all aspects described above. The invention must have a comprehensive and complete scope and be developed by an expert in the relevant field of art. These drawings are provided for accurate communication with individuals. The dimensions of the components are shown in the drawings. It may have been exaggerated for the sake of clarity. The subject matter of the examples described here is detailed to meet legal requirements. It has been explained in some way. However, the explanation itself limits the scope of this patent. It does not aim to do so. On the contrary, the inventor(s) believe that the subject matter requested in this document... including different features or combinations of features similar to those described, He predicted that it could be realized in other ways, along with other technologies. 7 In general, various aspects, including sample aspects, destroy microorganisms. It relates to the method of doing. As mentioned, the limitations of existing methods that require one or more steps In order to overcome, a person's body uses spikes to detoxify the viruses. a formulation and method are needed to destroy their proteins and related proteins It is ongoing. Therefore, the currently described invention deals with viruses and spike proteins. or offers a formulation and method for eliminating the relevant proteins. The phrase "destroying viruses, spike proteins, and related proteins" refers to destroying specific viruses. spike protein, a key structural protein found on its surface It refers to targeting and neutralizing. The term "host cell" refers to cells within an individual. Examples include epithelial cells. cells, nerve cells, red blood cells, white blood cells, spine, platelets, neuroglial cells, muscle cells, amniotic cells, and animals or Other such cells are found in humans. As used here, “spike proteins” or “related proteins” refer to proteins that interact with the host cell. a glycosylated viral protein that recognizes receptors on the cell membrane to bind to The terms "spike protein" and "related proteins" refer to each other in this technical description. It is used instead. The term "procreative cells" refers to cells that continue to produce or replicate spike proteins, It refers to cells containing spike protein. As used here, the term “storage cells” refers to cells that contain spike proteins in their cell membrane. However, it refers to cells that do not reproduce. As used here, the term “endothelial cell” refers to cells that form the lining of blood vessels and lymph nodes. It refers to the cells that line the inside of blood vessels. Endothelial cells are cells that connect a tissue to its surroundings. It regulates the transport of matter between them. As used here, the term “chelating agents” or “binders” refers to a substance that binds to a cell. components that bind to a receptor or chelate a virus and / or related proteins Examples include phenols, flavonoids, antioxidants, and carbohydrates. esters, polyphenols, flavanols, glycosides, or receptors in animals or humans 8 any other components that can bind to or chelate with them and Metabolites are involved. In this technical description, the terms "chelating agents" and "binders" are used. These expressions are used interchangeably. As used herein, the terms “syncytiums” or “conglomerates” refer to one or more It refers to a cell containing an excess of viruses and / or related proteins. These syncytiums, through the division of nuclei or the fusion of one or more single-celled organisms They can form and create a mass of cells. The terms “syncytiums” and “conglomerates” refer to these They are used interchangeably throughout the specification. As used here, the terms “senolytic compounds” or “mobilizers” refer to compounds that target viruses. and a cell's spike protein or related protein to activate It refers to the components involved in its breakdown / decomposition. These are called "senolitic compounds". The terms "mobilizers" are used interchangeably throughout this specification. As used here, "Angiotensin-converting enzyme 2 (ACE2) receptor" The term refers to a receptor located on the cell membrane that facilitates the entry of the virus into the cell. It expresses. As used here, the term "autophagy" refers to a cell's process of destroying a damaged part of itself. It describes a process of self-destruction. The currently described invention enables the extraction of viruses, spike proteins, and from any host cell. It is based on the elimination of the relevant proteins. Viral proteins infect host cells. can occur and remain persistent in these cells for a long time. Spike protein or related proteins. Viral proteins, such as these, have a high affinity for binding to cell receptors. It has; this leads to the formation of productive cells and storage cells. Productive These cells are those that continuously replicate the spike protein. These reproductive cells are living organisms. Viruses can form productive cell syncytiums containing virions and / or spikes. It can produce proteins. A storage cell, on the other hand, has spike proteins that remain around the cell membrane. However, these are cells that do not multiply. Some spike proteins are found on the host cell. and activated by host enzyme proteases for the fusion of one or more cells Interaction with the angiotensin-converting enzyme 2 (ACE2) receptor It tends to do so; this leads to the formation of syncytium or cell conglomerates. These productive cells and storage cells do not disappear spontaneously. 9 The formulation will inhibit multiple host cell receptors in addition to ACE2. It is structured in this way. Furthermore, the formulation includes furin (fusion enzyme) inhibitors. It includes several compounds that have been reported to have this function. As explained above, persistent spike proteins can contribute to health problems and neurological disorders. This can lead to disorders; therefore, eliminating these cells from a person's body A specific formulation and method are needed. The present invention destroys viruses, spike proteins, and related proteins from host cells. It involves a formulation aimed at eliminating microorganisms. Preferably, these microorganisms could be viruses. The formulation contains one or more phyto-support complexes, one or more supplements, and It may contain one or more auxiliary substances. In some ways, it can treat viruses, spikes The formulation targeting these proteins and related proteins may include: 15% w / v to One or more phytonutrient complexes in the range of 25% w / v; 5% w / v to 10% one or more supplements within the w / v range; and within the range of 55% w / v to 65% w / v It may contain one or more excipients (water). In some respects, one or more phyto-support complexes, one or more senolytic It may contain compounds and / or one or more chelating agents. In some respects, one or more phyto-support complexes also contribute to the entire chelation process. It includes agents and all senolytic compounds. In some respects, the formulation may contain one or more senolytic compounds. One or more more senolytic compounds, including but not limited to quercetin, rutin, EGCG, Curcumin, resveratrol, fisetin, glycyrrhizic acid, ginkgolide / bilobalide, fucoidan brown Algae, humic acid, clinoptilolite tuff, modified citrus pectin, Spirulina maxima, silicone It may contain dioxide and similar substances. The elements of the currently described invention, currently described including all types of senolitic compounds without deviating from the scope of the invention and / or otherwise It is designed to include this in a comprehensive manner. In some respects, the formulation may contain one or more chelating agents. One or more more chelating agents, including but not limited to fucoidan brown algae, Humic acid, clinoptilolite tuff, modified citrus pectin, Spirulina maxima, silicon dioxide, It may contain ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). Aspects of the currently disclosed invention, without deviating from the scope of the currently disclosed invention. to include and / or otherwise contain all types of chelating agents It has been designed. In some respects, one or more chelating agents may be involved, including but not limited to, the following: These are selected from a group that is not limited to: fucoidan in the range of 5% w / v to 15% w / v. brown algae; humic acid in the range of 3% w / v to 7% w / v; 2% w / v to 5% w / v clinoptilolite tuff in the range of 1% w / v to 4% w / v; citrus pectin in the range of 1% w / v to Spirulina maxima in the range of 3% w / v; silicon dioxide in the range of 0.5% w / v to 3% w / v; ethylenediaminetetraacetic acid (EDTA) in the range of 0.5% w / v to 3% w / v; and 0.5% w / v to 2% Diethylenetriaminepentaacetic acid (DTPA) and analogues in the w / v range. In some respects, one or more senolytic compounds may include, but not limited to, the following: It is selected from a non-restricted group: quercetin in the range of 1% w / v to 5% w / v; 1% w / v to Routine in the range of 4% w / v; EGCG in the range of 0.5% w / v to 3% w / v; 0.5% w / v to 2% w / v Curcumin in the range of 0.5% w / v to 2% w / v; resveratrol in the range of 0.5% w / v to 2% w / v fisetin in the range; glycyrrhizic acid ranging from 1% w / v to 4% w / v; 0.5% w / v to 2% w / v ginkgolide / bilobalide in the range of 5% w / v to 15% w / v; fucoidan brown Algae; humic acid in the range of 3% w / v to 7% w / v; humic acid in the range of 2% w / v to 5% w / v clinoptilolite tuff; modified citrus pectin in the range of 1% w / v to 4% w / v; 1% w / v to Spirulina maxima in the range of 3% w / v; and silicon dioxide in the range of 0.5% w / v to 3% w / v. and similar things. In some respects, one or more supplements, one or more bioactive supplements It is possible. In some ways, one or more bioactive supplements, minerals, vitamins, antioxidants, enzymes, amino acids, probiotics, prebiotics, and the like It may include, but is not limited to, aspects of the currently described invention. including all types of bioactive supplements without deviating from the scope of the invention and / or otherwise It is designed to include this in a comprehensive manner. In some respects, one or more auxiliary substances, solvents, water, oil, drying agents, Anticaking agents, binders, stabilizers, preservatives, emulsifiers, These may include, but are not limited to, pH adjusters and similar products. Available Aspects of the disclosed invention, each without deviating from the scope of the currently disclosed invention. to include and / or otherwise contain various auxiliary substances It has been designed. 11 Each component of the formulation was sourced commercially from India to prepare the formulation. It is provided as follows. In some respects, quercetin is found in Quercus sp., onions, apples, broccoli, green beans, oak, and It can be extracted from similar substances by solvent extraction method. Specifically, Quercetin reduces the size of syncytium, thereby decreasing viral protein expression. This can lead to a decrease. Additionally, quercetin affects the S2 fragments of the spike protein. It can inhibit its formation. In some respects, rutin, Sophora japonica, Viola tricolor, Styphnolobium japonicum, Fagopyrum esculentum or Morus alba, rope tree (sofora tree) and similar species. It can be extracted using the solvent extraction method. In some respects, epigallocatechin gallate (EGCG) is found in Camellia sinensis, Cistus incanus, and tea. It can be extracted from shrubs and similar plants using the solvent extraction method. Additionally, In some respects, epigallocatechin gallate (EGCG) derivatives can be used. Epigallocatechin Examples of gallate (EGCG) derivatives include, but are not limited to, theaflavin-3,3'- di-O-digallate (TFDG) is one example. In some respects, curcumin is a solvent derived from Curcuma longa, mango ginger, and the like. It can be extracted using an extraction method. In some respects, resveratrol is found in Polygoni cuspidati, grapevine leaves, raspberries, mulberries, plums, peanuts, synthetic resveratrol and similar substances by solvent extraction method It can be extracted. In some respects, fisetin resembles Rhus cotinus, strawberry, wig bush, and the like. It can be extracted using the solvent extraction method. In some respects, glycyrrhizic acid is derived from Glycyrrhiza glabra, Citrus paradisi, and similar plants. It can be extracted using the solvent extraction method. In some respects, ginkgolid / bilobalid, derived from Ginkgo biloba, ginkgo tree and similar things. It can be extracted using the solvent extraction method. In some respects, the formulation comes in capsule, syrup, hydrogel, suspension and similar forms. It can be improved. 12 In some respects, the use of the formulation may affect the virus and its spike proteins or related proteins. It could be to destroy proteins. In some respects, it is a process for destroying viruses, spike proteins, and related proteins. The treatment method is described. The method may include the following steps: a. viral components in the cells a. The breakdown of the cell membranes of virus-producing cells to release them into the external environment. inhibits the receptor binding sites of viruses, spike proteins, and related proteins. targeting by applying a formulation containing structured agents Preventing viral attachment to cells. In some respects, the formulation could be used in the treatment of viral infections. One or more senolytic compounds in the formulation will break down virus-producing cells. They can disrupt their membranes. In addition, one or more chelating agents can bind to viral receptor sites. It can connect. In some respects, a treatment method is being described. The method involves a. viral components in the cells. a. the breakdown of the cell membranes of virus-producing cells to release them into the external environment; and b. To inhibit the receptor binding sites of the spike protein, 15% w / v to 25% One or more phytonutrient complexes in the w / v range; 5% w / v to 10% w / v one or more supplements within the range of; and one in the range of 55% w / v to 65% w / v or by applying a formulation containing more or fewer excipients to the target This involves preventing viral attachment to cells. In some respects, for the destruction of viruses, spike proteins and related proteins, One or more phytonutrient complexes in the range of 15% w / v to 25% w / v; 5% One or more supplements ranging from w / v to 10% w / v; and 55% w / v to 65% The use of a formulation containing one or more excipients in the w / v range An explanation is provided. Figure 1 shows the formulation in accordance with one aspect of the currently described invention. It shows a flowchart illustrating a method for its preparation (100). Method (100) may include: In Step 102, to obtain a homogeneous mixture, a medium containing 15% w / v to 25% w / v Addition of one or a phyto support complex within this range. 13 In Step 104, one or more additives ranging from 0.1% w / v to 10% w / v are added to the homogenous mixture. chelating agent and one or more senolytic compounds in the range of 0.05% w / v to 5% w / v addition. In step 106, one or more supplements in the range of 5% w / v to 10% w / v and 50% w / v one or more excipients (water) in a homogeneous mixture in the range of up to 60% w / v addition. In step 108, the pH of the homogenous mixture is adjusted to a range of 3 to 5. In step 110, the homogeneous mixture is heated to a temperature of 50 to 60 degrees Celsius. In Step 112, the homogenous mixture is prepared to obtain a uniform particle size. Mixing and grinding the homogeneous mixture. Figure 2 illustrates an aspect of the currently described invention, namely the spike proteins or a flow showing the method of action of a formulation targeting the relevant proteins (200) It shows the diagram. The method may include the following steps: In step 202, the cell membranes of the virus-producing cells are broken down and the viral components are released. Release into the extracellular environment. In step 204, through the use of agents that inhibit receptor binding sites Preventing viral attachment to target cells. In some ways, the host viral attachment or by using agents that block cell receptors Preventing the spike protein from attaching to uninfected cells. Figure 3 shows how to eliminate viruses and spike proteins or related proteins through formulation. It shows a schematic representation of a method (300) for doing. The method (200) schematic representation, productive cell (A), storage cell (B), productive cell syncytium (C), endothelial cell (D), virus (E), spike protein (F), one or more It may contain a high concentration of senolytic compounds (G) and one or more chelating agents (H). Productive cells (A) are viral infections that spread to multiple cells in the host cell's body. Storage cells (B) may contain actively proliferating spike protein (F), which may be responsible. It contains stored spike protein (F) without replication properties. The generative cell syncytium (G) contains viruses that produce virions and / or spike proteins, or It may contain a cell conglomerate composed of senescent cells. Specifically, productive cells. 14 cells (A) form the syncytium of productive cells (C). Endothelial cells (D) form the blood These are the cells that line the vesicles. In some ways, the chelating agents in the formulation (H) may involve binding to a host cell receptor and / or fusion enzymes; Furthermore, viruses and / or spike proteins can enter the host cell or other parts of the body. It can block the fusion of cells. Examples of fusion enzymes include trypsin, Furin, TMPRSS2, and similar products may be found. Figure 4 shows the spike protein levels measured before and after the provocation step. It shows a graphical representation of a comparative display, based on the senolitic model. It reveals the functional effect of the release mechanism. Before the provocation, Spike levels appear minimal, negative, or below the detection threshold. the protein in immune cells and exosomes that traditional tests cannot reach This indicates that it remains sequestered within cellular structures. After the provocation, The shape shows a significant increase in measurable spike protein, and the senolytic compound... that it facilitates the breakdown of these cellular or vesicular compartments and more that it first enabled the release of the hidden spike protein into the bloodstream This confirms the observed change, which could not be detected by the standard baseline test. Because it reveals the true underlying spike load, the diagnostic aspect of the provocation method This highlights its value. This improved detection capability is shown in the figure. This constitutes a key advantage of the approach. In some respects, it involves the destruction of the virus and its spike protein or related proteins. A treatment method targeting viral components can be described. The method may include the following steps: a. viral components To break down the cell membranes of cells that produce viruses for release into the extracellular environment; and b. Configured to inhibit receptor binding sites of spike protein By applying a formulation containing agents, viral attachment to target cells is achieved. to prevent it from happening. In one example application, the goal is to destroy the virus and its spike protein or related proteins. A kit (not shown) or device is described. The kit or device includes one or more It may contain capsules. One or more of the capsules may contain one or more senolytic agents. It may contain compounds. One or more capsules may contain other chelating agents. It may contain an agent. In some applications, the detoxification protocol involves removing freely circulating substances from the bloodstream. enzymatic breakdown of floating viral particles and / or spike proteins This includes an additional step aimed at the senolytic mediation of infected cells. spike-binding agents for cleaning and preventing re-entry of the virus This is carried out in parallel with the application. Suitable enzymes include: including but not limited to proteolytic agents such as nattokinase, serrapeptase, and bromelain. enzymes or other proteases that can break down viral proteins or spike structures These enzymes are found to increase the overall efficiency and safety of detoxification. for this purpose, orally, intravenously, or in combination with senolytic and binding agents. applicable. In another instance, the provocation protocol is called "Revive". application of the formulation capsules and subsequent enzymatic component co- It may include implementation in a timed or sequential manner. In some applications, the detoxification protocol takes approximately [number] minutes after the administration of senolytic compounds. This causes a temporary increase in circulating spike protein levels after 1.5–2 hours. This phenomenon results from the selective destruction of aged or virus-containing cells. This occurs, and during this process, intracellular spike proteins are released into the bloodstream. It is temporary. spike increase, persistent spike or viral presence that is not detectable under normal conditions It allows for extremely precise scanning. Referred to as a "provocation protocol". This approach, called spike protein levels, increases within 1–4 hours after application. This results in measurement using a test specific to the spike. In some applications, the detoxification protocol also includes senolytic-mediated cell cleansing. then free-swimming spike proteins and / or viral agents are released into the bloodstream It also involves the enzymatic breakdown of particles. Suitable enzymes among them nattokinase, serrapeptase, bromelain or spike protein structures Other proteases capable of breaking them down exist. Enzymatic breakdown, detoxification. with senolytic and spike bonding steps to increase its efficiency and safety It can occur simultaneously or after these events. Nattokinase extracellular effect Since it has been shown, cell disruption by senolytic agents is a precursor to enzymatic activity. It is a condition. 16 In another application, it involves the detoxification of viruses or spike proteins in a subject. A method is described that includes the following: (a) selective use of virus-containing cells by one or more senolytic agents its disintegration as; (b) application of one or more spike-binding agents to the host cell by blocking their receptors and inhibiting fusion enzymes Preventing the re-entry of viral or spike proteins into host cells; and (c) one or more of the following capable of performing proteolytic degradation of viral proteins by applying more enzymes, freely floating in the bloodstream Breakdown of virus and / or spike proteins. In another application, the method involves the enzyme nattokinase. In another application, the enzymes nattokinase, serrapeptase, bromelain, or these are used. It is selected from combinations. In another application, the detection of intracellular persistent spike proteins for diagnostic purposes. to increase the dose, approximately 1.5–2 hours after application of the senolytic agent. a method to temporarily increase circulating spike protein levels It is explained. In an example application, to destroy viruses and their spike protein or related proteins The formulation for this purpose includes the components shown in Table 1: Table 1- Component Category Component Concentration (% w / v) Phyto Support Complex Quercetin 3% to 4% Routine 3% to 4% Epigallocatechin Gallate (EGCG) 1.5% to 2.5% 17 Curcumin 1.5% to 2.5% Resveratrol 1.5% to 2.5% Fisetin 1.5% to 2.5% Glycyrrhizic acid 1.5% to 2.5% Ginkgolide / Bilobalide 1.5% to 2.5% Chelating Agents and Supplements Fucoidan Brown Algae 2% to 3% Humic Acid 2% to 3% Clinoptilolite Tuff 1.5% to 2.5% Modified Citrus Pectin 1.5% to 2.5% Spirulina maxima 0.5% to 1.5% Silicon Dioxide 0.5% to 1.5% Excipients: Water or oil (solvent) 60% to 80% Examples This explanation will now be illustrated with working examples; the purpose of these examples is to show that... The purpose is to demonstrate the functioning of the disclosure and to relate to the scope of the currently disclosed invention. This is not to imply any limitation in a restrictive way. Unless otherwise stated, All technical and scientific terms used herein belong to the technical field to which this explanation belongs. It carries the meaning generally understood by someone who is an expert in the field. The methods and... 18 in the application of formulations similar or equivalent to those described herein Although various methods and materials can be used, the methods presented here are examples. The devices and materials are described. This description includes the methods and not limited by experimental conditions, since such methods and conditions are variable. It should be understood that it can be demonstrated. Example 1: As an example, formulations aimed at targeting spike protein are used in phytotherapy. It is formulated to include a complex containing 3.5% w / v Quercetin and 3.5% w / v Rutin. 2.0% w / v Epigallocatechin gallate (EGCG), 2.0% w / v Curcumin, 2.0% w / v Resveratrol, It contains 2.0% w / v Fisetin, 2.0% w / v Glycyrrhizic acid, and 2.0% w / v Ginkgolide / Bilobalide. Chelating agents and supplements, 2.5% w / v Fukoidan brown algae, 2.5% w / v Humic acid, 2.0% w / v; Clinoptilolite tuff, 2.0% w / v; Modified Citrus Pectin, 1.0% w / v It contains Spirulina maxima and 1.0% w / v Silicon dioxide. The excipient used is: It is 70.0% w / v water or oil (solvent). Example 2: As another example, the formulation includes one or more phytosupport complexes, one or more supplements (or bioactive supplements) and one or more auxiliary supplements It is formulated to include the following ingredients. Preferably, one or more phytonutrients. the complex contains one or more senolytic compounds as shown in Table 2. It includes. Formulation Components Concentration % w / v One or phyto supplement complex Quercetin 2.5 Routine 4 EGCG 2.5 Curcumin 2.5 Resveratrol 2 Fisetin 2.5 One or more Selenium 4 supplements 19 Soluble vitamin One or more Excipient Drying agent 80 Anti-caking agents A solvent such as water or oil. Table 2 Example 3: As another example, one or more phyto-support complexes in the formulation, As shown in Table 3, one or more senolitic compounds and one or more It is formulated to include a chelating agent. Components Function Concentration % w / v Quercetin Cell lysis and chelation 3 Routine Cell Disintegration and Chelation 3 EGCG Cell lysis and chelation 2 Curcumin Cell lysis and chelation 2 Resveratrol Cell breakdown 2 Fisetin Cell Disintegration 2 Fucoidan brown Algae Chelating Agent 3 Humic acid Chelating agent 3 Clinoptilolite tuff Chelating agent 2 Modified citrus pectin Chelating agent 2 Spirulina maxima Chelating agent 1 Water Auxiliary substance 75 Table 3 Example 4: In a clinical trial, it was found that those who contracted COVID-19 in 2022 would be able to work. The 43-year-old male patient (or patient X), whose concentration was impaired, The patient continued to experience mild neurological complaints, including disorders. He underwent treatment with various other therapies for two years. Despite this, he experienced a serious relapse. without recall of infection, after two years of treatment, the PBMCs (immune The intracellular charge of spike proteins (in cells) is unusually high. It remains. After administering supportive dietary supplements for 8 weeks, the second Intracellular spike protein levels in PBMCs decreased by 90% in the control group. It has been revealed that... Treatment has been continued with nutritional supplements, and the dosage has been adjusted according to clinical practice. adjusted based on recovery (decrease in spike protein concentration) (given in Tables 4 to 6 below). Table 4 - This shows the presence of spike protein in immune cells (PBMC) in the initial tests. It shows. Spike protein in plasma / serum is negative. Spike protein in exosomes is negative. Spike in immune cells (PBMC) Protein Positive - 188.04 pg / 2.5 × 10⁻⁶ 6 cells Vaccine in PBMC (Pulmonary Immune Cells) mRNA Negative In immune cells (PBMC) SARS-CoV-2 RNA (persistence) Negative Observation - In July 2024, Patient X used phytoactive compounds formulated in an aqueous medium, The current product is obtained from a mixture of chelating agents and excipients. He started a treatment regimen with the Liquid Spectrum formulation. The initially prescribed dosage was 25 ml to be taken orally twice daily. Significant improvements in clinical and laboratory results over seven weeks. It has been observed. 21 Table 5 - This is after 8 weeks of administering supportive dietary supplements. It demonstrates the presence of spike protein in primary immune cells (PBMC). Spike protein in plasma / serum is negative. Spike protein in exosomes is negative. Spike in immune cells (PBMC) Protein Positive - 17.28 pg / 2.5 × 10⁻⁶ 6 cells Observation - As of September 2024, after eight weeks of treatment, cell count in PBMCs Intra-spike protein levels decreased by 90% to 17.28 pg / 2.5 × 10^6 cells. It has fallen. Table 6 - This is the presence of spike protein in immune cells (PBMC) after one month. This shows that it has been reduced to almost zero. Spike protein in plasma / serum is negative. Spike protein in exosomes is negative. Spike in immune cells (PBMC) Protein Positive - 5.18 pg / 2.5 × 10 6 cells Observation - Therapeutic effects persisted and levels were 5.18 pg / 2.5 as of October 2024. It has been further reduced to as little as 10^6 cells. Final Result: The current formulation leads to significant improvements over time. It has opened. ● In July 2024, the baseline spike protein level in PBMCs was 188 pg / 2.5 × It is saved as 10^6 cells. ● Seven weeks after treatment, as of September 2024, spike protein level was 17.28 It showed a 90% reduction, falling to pg / 2.5 × 10^6 cells; therapeutic apheresis however, it had no effect on spike protein levels in PBMCs. He hasn't shown it. 22 ● Twelve weeks after treatment, in October 2024, spike protein level was 5.18 pg / 2.5 × It has been further reduced to 10^6 cells, and without the use of blood thinners. Microthrombi have disappeared; however, this data has not been shown. ● In addition, a significant improvement in neurological symptoms has been observed, and Concentration ability has been restored. ● By November 2024, continued use of the formulation will be beneficial, both leading to lasting improvements in both symptoms and laboratory markers. It has opened. Furthermore, the formulation was primarily designed to address suspected heavy metal toxicity, but... It has also been applied in cases where standard tests do not show high levels. Furthermore, patients with spike exposure may experience neurological problems or organ dysfunction. It has also been used in cases where potentially related symptoms are observed. The aim of the approach is to remove the fat and other tissues in which they are stored due to previous exposures. by stimulating spike release from storage areas, including metal in the body The aim is to ensure that accumulated wealth is evaluated more accurately. Example 5: In another clinical trial, long COVID / Postvac and chronic inflammation A 41-year-old female patient with persistent symptoms, including ISGI / joints. (or patient Y, as they may be referred to) took supportive dietary supplements for four weeks. After receiving it, she underwent a follow-up examination in September. The results were... Quantification showed a negative result in terms of spike (spike protein). The decrease in concentration is given in Tables 7 and 8 below. Before treatment with the formulation begins, laboratory tests were conducted in October 2024. tests showed high levels of spike protein (228.82 pg / ml) in exosomes and high Microthrombus levels were revealed (by flow cytometry). However, at that time... Spike protein levels were not detected in plasma and PBMCs. The patient died on December 1. They started receiving formulation supplements in 2024 and then had their first dose on December 10, 2024. He underwent inuspheresis treatment. Despite work-related stress and frequent travel, he experienced mild symptoms. Improvements have been observed. Table 7 - This shows the spike protein in exosomes and immune cells in the initial tests. (PBMC) indicates the presence of spike protein. 23 Spike protein in plasma / serum is negative. Spike protein in exosomes Positive - 228.82 pg / ml Spike in immune cells (PBMC) protein Negative Observation - Spike protein in exosomes is Positive - 228.82 pg / ml. It has been observed. Table 8 - This table shows the levels in exosomes after 4 weeks of administration of the current formulation. and demonstrates the presence of spike protein in immune cells (PBMC). Spike protein in plasma / serum is negative. Spike protein in exosomes: Positive - 14.25 pg / ml Spike in immune cells (PBMC) Protein Positive - 9.80 pg / 2.5 x 10 ⁶cell Observation - Taking the formulation along with dietary supplements for 4 weeks Subsequently, no spike protein was observed. Final Result: - In October 2024 (Initial), spike protein levels in exosomes were 228.82 pg / ml. However, spike protein was undetectable in plasma and PBMCs. Microthrombi were elevated. Treatment was initiated on December 1, 2024. - As of December 11, 2024, spike protein levels in exosomes will reach 14.25 pg / ml. decreased (i.e., approximately a 94% reduction) and spike protein levels in PBMCs. It has been newly determined as 9.80 pg / 2.5 × 10^6 cells. Patient X's case illustrates the persistent spike protein-associated pathologies observed in Long COVID. The study revealed the therapeutic potential of the formulation in addressing the persistent spike. Protein expression is a chronic condition central to long COVID pathology. It has been associated with inflammation, immune dysregulation, and endothelial damage. 24 In patient X's case, administration of the formulation resulted in intracellular spikes within seven weeks. This led to a significant decrease in protein levels, which were 188 pg / 2.5 It decreased from 10^6 cells to 17.28 pg / 2.5 × 10^6 cells; this is a 90% reduction. This is important in neurological symptoms, especially difficulties concentrating. Improvements have been observed. Intracellular spike protein levels reached 5.18 pg / 2.5 × 10^6 cells after 12 weeks. its permanent decline, unlike previous interventions in the formulation, is long-term. This suggests that it could provide benefits. The improvement in both patients was likely due to a multifactorial effect of the formulation. It underlines the mechanism of the formulation, which is different from traditional anticoagulants. as evidenced by microscopic evaluations without its use It has been observed to eliminate microthrombi. This result is attributed to the natural ingredients in the formulation. The compounds have been associated with anti-inflammatory and anti-thrombotic properties. Clinical trials of these findings show that the rapid and sustainable results observed in both patients This was further supported by symptomatic improvements within seven weeks of treatment. The patient has a common but debilitating symptom of Long COVID. They reported a significant improvement in their concentration abilities. The formulation... With continued use, these improvements were maintained and even improved by week 12. has increased. Such results suggest that targeting the intracellular spike protein is beneficial for long-term COVID-19. It highlights the potential of the formulation to be one of the cornerstones of management. Its use involves spikes in exosomes within six weeks of initiating treatment. It showed a remarkable 94% decrease in protein levels. Table 9 - This shows the results in multiple subjects before and after senolytic provocation. This shows a comparison of spike protein levels (Before Provocation). Spike Levels). PRE-PROVOCATION SPIKE LEVELS: 235 pg Spike protein in plasma / serum is NEGATIVE. Spike protein in exosomes POSITIVE 235.94 pg / ml Immune cell (PBMC) spike POSITIVE 8.23 ​​pg / 2.5×10 cells⁶ protein PRE-PROVOCATION SPIKE LEVELS: 1131 pg Spike protein in plasma / serum is NEGATIVE. Spike protein in exosomes POSITIVE 1131.84 pg / ml Spike in immune cells (PBMC) protein NEGATIVE Observation - While most subjects initially showed negative spike levels, many It turns positive after provocation; this indicates that the spike protein is only It becomes detectable after its release via senolytic stimulation. It shows. Table 10 – This is the spike measured between subjects before and after the provocation step. It shows a comparative analysis of protein levels. ID ID Kit Spike Glycoprotein Spike PP 72 #53 before 6.3 ND 73 #53 then 33.7 2.9 Observation - Data shows that many subjects changed from a negative to a positive result after provocation. This indicates that it has passed; this situation cannot be detected in the initial conditions of the method. This shows that it makes it possible to identify the spike protein that remains in this state. Table 11 - This is the spike protein measured before and after senolytic provocation. It shows the levels. Detectable spike following provocation. A significant increase in levels is observed. Average hemoglobin according to its value not standardized the previous spike Average according to hemoglobin standardized spike Standardized difference Standardized difference (%) 26 NEG POZ 63.1★ 62.1 %6214 NEG ★ POZ 44.7 33.8 %316 NEG NEG 21.3 8.0 54% POSITION ★ ★ POSITION 91.6 43.3 %111 NEG NEG 12.3 10.1 %314 POSITION ★ ★ POSITION 70.5 9.6 %14 POSITION ★ ★ POSITION 46.6 9.1 %24 NEG POZ 115.1★ 92.2 %415 NEG POZ 33.7★ 5.2 %17 NEG POZ 66.1★ 50.5 %339 NEG POZ 60.9★ 38.3 %169 POSITION ★ POSITION 48.1★ 17.9 %54 NEG POZ 33.2★ 18.0 %122 PROVOCATION PREVIOUS SPIKE LEVELS With “REVIVE / SENOLESCENCE” CAPSULES SPIKE LEVELS 2 HOURS AFTER THE PROVOCATION. Observation - Table 11, before and after application of the senolytic provocation capsule. then comparative spike protein levels measured across multiple subjects It offers. A clear pattern emerges; accordingly, a significant number of subjects, Prior to the provocation, it shows NEG (below the detection limit) spike levels. However, following this provocative step, what was previously negative... Many of the samples are converting to POZ, and this indicates that the spike protein is only The table shows that it is measurable after senolytic stimulation. The table also shows that, 27 It includes a note stating "MASS SPEC LOD: 30.0", indicating a concentration above 30 pg / mL. This indicates that the values ​​are considered positive in this test method. Negative The transition from negative to positive results occurs when the spike protein in the cell acts before the provocation. it may be sequestered within or in vesicular structures and that as a result, it has become undetectable by routine tests. This suggests that following the provocation, the senolytic mixture spike protein It appears to release it into the bloodstream, thus making it impossible to detect. It makes it possible. The advantages of the present invention include the following: ● Enhanced Efficiency: One or more pluripotent compounds and in abundance Integrating the binder and mobilizer increases the effectiveness of the method. ● Improved Sensitivity: Sensitivity to one or more senolitic compounds and The integration of chelating / binding agents increases the sensitivity of the method. ● The current formulation offers benefits in terms of protecting organs during detoxification. What is important is the formation of cell fusion caused by spike proteins. prevents. The above description, examples, and explanations relate to the currently disclosed invention. It is presented for these purposes. The invention described herein, in the form or form described herein, It is not intended to be limited to certain forms. In the Detailed Explanation above, for example, Various features of the currently described invention, making the description more fluent. For this purpose, they are grouped within one or more directions, configurations, or orientations. The characteristics of the aspects, configurations, or directions differ from those discussed above. Alternative directions, configurations, or orientations can be combined within this explanation. the method, more than what is expressly stated in each claim of the currently described invention This should not be interpreted in a way that reflects an intention to suggest that the characteristic is required. On the contrary, As reflected in the claims below, the inventive aspects are the only ones described above. It lies in less than all the characteristics of an aspect, structure, or orientation. Therefore, the following claims each represent a separate aspect of the invention described herein. It is included in this Detailed Description as a standalone document. 28 Furthermore, the currently described invention may involve one or more aspects, configurations, or Although it includes a description of the direction and specific variations and changes. After the existing invention is understood, for example by people who are experts in the field other variations, combinations and that may be within the scope of their knowledge and skills The changes are also within the scope of the currently described invention. To the extent permitted, Alternative, interchangeable and / or equivalent to those specified in the requests. alternative aspects, configurations, or steps that include structures, functions, ranges, or steps The aim is to obtain rights encompassing these aspects; the alternative in question, interchangeable and / or equivalent structures, functions, ranges, or steps any patentable subject matter, whether disclosed herein or not, is made public. without the intention of allocation.

Claims

29 REQUESTS 1. A formulation designed to target viruses, spike proteins, and related proteins. and includes the following: One or more phytonutrients in the range of 15% w / v to 25% w / v. complex; One or more supplements in the range of 5% w / v to 10% w / v; and One or more excipients in the range of 55% w / v to 65% w / v.

2. Formulation according to Claim 1, whereby one or more phytonutrients are involved. The complex also contains one or more chelating agents and / or one or more It contains a senolytic compound.

3. Formulation according to Claim 1, whereby one or more phyto-supportive products are involved. The complex includes all chelating agents and all senolytic compounds.

4. Formulation according to Claim 2, wherein one or more chelating agents are involved. agent, fucoidan brown algae in the range of 5% w / v to 15% w / v; 3% w / v to 7% w / v humic acid in the range; clinoptilolite tuff ranging from 2% w / v to 5% w / v; 1% w / v to 4% w / v Citrus pectin in the range of 1% w / v to 3% w / v; Spirulina maxima in the range of 0.5% w / v silicon dioxide in the range of 0.5% w / v to 3% w / v ethylenediaminetetraacetic acid (EDTA); and in the range of 0.5% w / v to 2% w / v It is selected from a group containing diethylenetriaminepentaacetic acid (DTPA).

5. This is a formulation targeting the spike protein according to Claim 2, and hereinafter referred to as such. one or more senolytic compounds, quercetin in the range of 1% w / v to 5% w / v; 1% w / v to Routine in the range of 4% w / v; EGCG in the range of 0.5% w / v to 3% w / v; 0.5% w / v to 2% w / v Curcumin in the range of 0.5% w / v to 2% w / v; resveratrol in the range of 0.5% w / v to 2% w / v fisetin in the range; glycyrrhizic acid ranging from 1% w / v to 4% w / v; 0.5% w / v to 2% w / v ginkgolide / bilobalide in the range of 5% w / v to 15% w / v; fucoidan brown Algae; humic acid in the range of 3% w / v to 7% w / v; humic acid in the range of 2% w / v to 5% w / v clinoptilolite tuff; modified citrus pectin in the range of 1% w / v to 4% w / v; 1% w / v to Spirulina maxima in the range of 3% w / v; and silicon dioxide in the range of 0.5% w / v to 3% w / v. It is selected from a group that includes.

6. Formulation according to Claim 2, wherein one or more chelating agents are involved. the agent acts on cells, viruses, and spike proteins or proteins associated with them. It blocks receptors.

7. Formulation according to Claim 2, wherein one or more senolitic compounds are involved. It breaks down compound cells and viruses, spike proteins, or related substances. It mobilizes proteins.

8. A formulation according to Claim 1, wherein one or more supplements, minerals, vitamins, antioxidants, enzymes, amino acids, probiotics and prebiotics is selected from a group.

9. Formulation according to Claim 1, wherein one or more auxiliary substances are involved. Ingredients: water, oil, drying agents, anti-caking agents, binders, from a group that includes stabilizers, preservatives, emulsifiers and pH adjusters. is selected.

10. Formulation according to Claim 1, wherein the formulation in question is a capsule, syrup, It is developed in the form of a hydrogel or suspension.

11. A formulation preparation method (100) includes the following steps: a. In Step 102, to obtain a homogeneous mixture, 15% w / v to a medium is added. Addition of one or more phytosupport complexes within a 25% w / v range. b. In Step 104, one or more additives ranging from 0.1% w / v to 10% w / v are added to the homogenous mixture. excess chelating agent and one or more in the range of 0.05% w / v to 5% w / v Addition of senolytic compounds. c. In Step 106, one or more supplements in the range of 5% w / v to 10% w / v and 50% w / v to 60% w / v of one or more excipients (water) Adding to a homogeneous mixture. d. In Step 108, adjust the pH of the homogenous mixture to a range of 3 to 5. e. In Step 110, the homogeneous mixture is heated to a temperature of 50 to 60 degrees Celsius. heating. 31 12. A method of preparing a formulation according to claim 11 is (100), wherein it is said Method (100) also involves homogenizing the mixture in order to obtain a uniform particle size. It includes the mixing and grinding step of the homogeneous mixture (112).

13. Mechanism of action of a formulation aimed at targeting the spike protein. one method (200) is related and includes the following: Virus-producing cells release viral components into the extracellular environment. the breakdown of membranes (202); and Target cells are targeted using agents that inhibit receptor binding sites. Prevention of viral attachment (204).

14. According to claim 13, the method is (200), where one or more senolytic compounds, It breaks down the cell membranes of virus-producing cells.

15. According to claim 13, the method is (200), where one or more chelating agents, It is able to bind to viral receptor sites.

16. According to claim 13, the method is (200), where the breakdown of cell membranes, viral This involves targeting cells that contain particles or viral proteins.

17. A method for treating viruses, spike proteins, and related proteins. and the method in question includes the following: a. cells that produce viruses release viral components into the extracellular environment rupture of membranes; b. To inhibit the receptor binding sites of the spike protein, 15% w / v to One or more phytonutrient complexes in the 25% w / v range; 5% w / v one or more supplements in the range of 10% w / v; and 55% w / v to 65% a formulation containing one or more excipients in the w / v range Preventing viral attachment to target cells through application.

18. The method according to claim 17, whereby one or more senolytic compounds, viruses It breaks down the cell membranes of the producing cells. 32 19. The method according to claim 17, whereby one or more chelating agents are viral It is able to bind to receptor sites.

20. For the elimination of viruses, spike proteins and related proteins; 15% w / v to One or more phytonutrient complexes in the range of 25% w / v; 5% w / v to 10% one or more supplements within the w / v range; and within the range of 55% w / v to 65% w / v It is the use of a formulation containing one or more excipients.

21. A method for detoxifying viral or spike proteins in a subject. and the method in question includes the following: (a) selective use of virus-containing cells by one or more senolytic agents its disintegration as; (b) application of one or more spike-binding agents to the host cell by blocking their receptors and inhibiting fusion enzymes Preventing the re-entry of viral or spike proteins into host cells; and (c) one or more of the following capable of performing proteolytic degradation of viral proteins by applying more enzymes, freely floating in the bloodstream Breakdown of virus and / or spike proteins.

22. The method is based on claim 21, and the enzyme in question is nattokinase.

23. The method according to claim 21, where the enzyme in question is nattokinase, serrapeptase, It is selected from bromelain or combinations thereof.

24. To increase the detection of persistent intracellular spike proteins for diagnostic purposes. approximately 1.5–2 hours after the application of one or more senolytic agents. a method aimed at temporarily raising circulating spike protein levels It is a method.

Images